Abstract and Introduction
Migraine is a highly prevalent disorder in women associated with significant disability. Yet it remains underdiagnosed and undertreated. Recent advances in our understanding of the pathophysiology of migraine, including the role of calcitonin gene-related peptide, has led to the development of new targeted migraine therapies. It is important for all healthcare professionals caring for women to be familiar with the diagnostic criteria for migraine and for them to follow a stepwise approach to management of acute and chronic migraine that comprises biobehavioral and pharmacologic management, particularly the more recently approved therapies.
Migraine is a chronic disorder affecting 18% of women worldwide—a prevalence rate three times that of men. Most reproductive-aged women who report episodic headache have migraine. Despite recent advances in our understanding of migraine pathophysiology and new FDA-approved targeted migraine therapies, migraine remains underdiagnosed and undertreated.
Menopause. 2022;29(5):606-608. © 2022 The North American Menopause Society